Michael B. Mason
Known title: Sr. VP & Pres., Lilly DiabetesCIK: 0001799419
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| WW | ▲ Buy | Grant | 1,166 | $0 | 1/2/2026 | View on chart |
| WW | ▲ Buy | Grant | 1,219 | $0 | 12/19/2025 | View on chart |
| LLY | ▲ Buy | Grant | 8,023 | $2.8M | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 6,690 | $0 | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,935 | $1.0M | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 2,612 | $635K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
WW International Reports Momentum in GLP-1 Care and Cash Flow
WW International is highlighting a potential cash flow turnaround driven by growing momentum in its GLP-1 care services. This development is relevant to the company's broader strategy as it seeks to adapt to changes in the weight management market. The stock currently trades near its support level, with analysts maintaining a higher average price target than the current market price.
WW International Reports Momentum in GLP-1 Care and Cash Flow. WW International is highlighting a potential cash flow turnaround driven by growing momentum in its GLP-1 care services. This development is relevant to the company's broader strategy as it seeks to adapt to changes in the weight management market. The stock currently trades near its support level, with analysts maintaining a higher average price target than the current market price.